Ponsegromab

**Semantic type:** Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance

**Definition:** A monoclonal antibody directed against the human growth differentiation factor 15 (GDF15; MIC-1), with potential anti-cachexia activity. Upon administration, ponsegromab targets and binds to GDF15, thereby preventing the binding of GDF15 to its receptor glial-cell-derived neurotrophic factor (GDNF) family receptor alpha-like (GFRAL) and blocking GDF15/GFRAL-mediated signaling. This may abrogate loss of appetite and uncontrolled weight loss associated with high serum levels of GDF15. GDF15, a stress response cytokine and divergent member of the transforming growth factor beta (TGF-beta) superfamily, plays a key role in the regulation of body weight through central mechanisms. High GDF15 plasma levels, as seen in individuals with advanced cancers, are associated with loss of body mass.

**Synonyms:** - PF 06946860 - PF-06946860 - PF06946860 - PONSEGROMAB